With Russia being the first country to approve a Covid-19 vaccine for widespread public use, discussions began on the availability and production of the Russian vaccine for people from other countries.
However, concerns about the effectiveness of the vaccine remain unaddressed, as the Russian government has cleared the way for the general use of the vaccine without conducting phase III clinical trials, according to the Indian Express report.
The vaccine developed by the Moscow based Gamaleya Institute began human trials just two months ago.
Other vaccine candidates who have so far been at the forefront of the race to produce a vaccine, including Oxford-AstraZeneca and America’s Moderna, have begun their human trials before the Russian vaccine, but their vaccines are not expected to be approved for general use before the beginning of next year.
Production and Availability of Russian Vaccine in India
In addition to the Gamaleya Institute’s facilities where the vaccine is produced, Sistema, one of the largest business groups in Russia, decided to produce the vaccine.
The business group said it plans to produce about 15 lakhs doses of the vaccine a year.
However, due to the huge demand for the vaccine and the limited ability of Russian pharmaceutical companies to meet demand, it may take a long time for the vaccine to be available to people in other countries.
Although no country has publicly expressed interest in buying the Russian vaccine, a Reuters news report quoted the director of the Russian sovereign wealth fund as saying that other countries have requested a dose of the vaccine of more than 100 million rupees.
Availability of Russian vaccine in India
In accordance with the measure adopted by the Government of India for other candidate vaccines, CDSCO is expected to require Russia to implement phase II and III human trials in the Indian population before giving its consent for general use.
The government has taken a similar stance on the Oxford-AstraZeneca vaccine, which is expected to start phase 3 trials this week.
Clinical trials in the late stages are becoming important as the Russian vaccine update will be administered to a large portion of the population and it is also necessary to test its efficacy in different populations before it is approved for general use.
Taking into account the exceptional situation facing the country, CDSCO has the right to grant emergency approval to use the vaccine as it did for Remdesivir in Coronavirus patients without conducting its clinical trials.
However, granting approval to administer a drug to a limited number of people who already have the disease differs from agreeing to use a vaccine that will be administered to a large portion of the population.
Production Agreements for Russian vaccine
So far, no pharmaceutical company in India has signed an agreement to produce and develop a vaccine with the Gamaleya Institute, which produced the Russian vaccine.
And the Serum Institute in India, which has signed production agreements with Oxford AstraZeneca and other candidate vaccines, has not signed any agreements with Russian vaccine manufacturers.
Indian scientists are also studying other vaccines against COVID-19, including those developed by British-Swedish pharmaceutical company AstraZeneca and American Moderna-NIAID.
MOSCOW, Aug. 18 (TASS /). The Indian Express newspaper, citing government sources, reported that India, through its embassy in Moscow, had established contacts with the Russian developer of the Sputnik V vaccine against the novel coronavirus infection.
Samples of these vaccines are currently in various stages of clinical trials, including in Indian medical institutions.
On Monday, a private national group of virology experts recommended that the Indian government consider the issue of obtaining these preparations.
The Fist Country Russia Register Corona Vaccine
On August 11, Russia became the first country in the world to register a coronavirus vaccine called Sputnik V. The preparation was developed by the Gamaleya National Research Institute of Epidemiological and Microbiology Research of the Russian Ministry of Health. It passed the clinical trials in June and July.
Sputnik V Vaccine in India
India will produce 300 million doses of the vaccine, according to reports. The update comes in the context of Russia’s previous announcement that it has quickly tracked down its recently released Sputnik V vaccine and is likely to release it for civilian use soon, according to a report and also COVID 19 Vaccine Price in India is suitable for all categories.
The Gamaleya Research Institute of research said the Sputnik V COVID vaccine, developed by the Aesthetic Research Institute of Epidemiology and Microbiology of the Russian Ministry of Health, may be permitted to release a batch of vaccine for civilian use. Associate Member of the Russian Academy of Sciences Denis Loginov, according to a report.